Quick News Bit

FDA Allows Some J&J Vaccine Doses From Troubled Facility


The FDA announced Friday that batches of Johnson & Johnson COVID-19 vaccine manufactured at Emergent BioSolutions’ beleaguered facility will be authorized under emergency use authorization (EUA) for use.

However, in a highly unusual move, the agency said it is only authorizing the vaccine batches under EUA, not the manufacturing facility itself.

In order to fill a “critically needed supply” of Johnson & Johnson COVID-19 vaccine, the FDA said it is authorizing two batches of “vaccine drug substance” manufactured at the Emergent BioSolutions plant in Baltimore. While the agency characterized the batches as “suitable for use,” it added, “the FDA is not yet ready to include the Emergent BioSolutions plant in the [Johnson & Johnson] EUA as an authorized manufacturing facility.”


According to the New York Times, the FDA told Emergent that 60 million batches of vaccine cannot be used, and only 10 million doses can be kept. The company recently came under fire from Congress about its spoiled doses.

In its statement, the FDA said “additional [vaccine] batches are still under review.”

These authorized batches can either be used in the U.S. or sent to other countries, and the FDA said it revised the authorization of the Johnson & Johnson vaccine to ensure that distribution and administration of these vaccines are in line with the recipient countries’ laws.


Separately, following additional information from Johnson & Johnson, the agency said it will also extend the vaccine’s expiration dating to 4.5 months from 3 months when kept at 2 to 8º C.

“These actions followed an extensive review of records, including the production history of the facility and the testing performed to evaluate the quality of the product. This review has been taking place while Emergent BioSolutions prepares to resume manufacturing operations with corrective actions to ensure compliance with the FDA’s current good manufacturing practice requirements,” said Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research, in a statement.

The agency said it is continuing to work through issues with Johnson & Johnson and Emergent BioSolutions management.

  • Molly Walker is deputy managing editor and covers infectious diseases for MedPage Today. She is a 2020 J2 Achievement Award winner for her COVID-19 coverage. Follow


For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Leave a comment